NBIX · Neurocrine Biosciences Inc · Documents
$144.89
-1.12 (-0.76%)
At close · Oct 28
Return incl. dividend (before tax)
Q2 2026 earnings call transcript
Market Cap
$14.84B
Shares
101.65M
Volume · Oct 28
555.59K
Avg daily vol (3M)
1.32M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 8-K | Neurocrine Biosciences, Inc. appointed Eiry W. Roberts, M.D. as Chief Medical Officer effective September 28, 2026, succeeding Sanjay Keswani, M.D., whose service ended September 25, 2026; Dr. Keswani is entitled to severance benefits under the Executive Severance Plan. | 2026-09-28 | 2026-09-25 | |
| Investor Event Transcript | — | 2026-09-15 | 2026-09-30 | |
| Investor Event Transcript | — | 2026-09-09 | 2026-09-30 | |
| 8-K/A | — | 2026-07-31 | 2026-05-14 | |
| 10-Q | — | 2026-07-31 | 2026-06-30 | |
| 8-K | — | 2026-07-30 | — | |
| 8-K | — | 2026-05-28 | 2026-05-27 | |
| Investor Event Transcript | — | 2026-05-26 | 2026-06-30 | |
| Investor Event Transcript | — | 2026-05-26 | 2026-06-30 | |
| 8-K | — | 2026-05-18 | 2026-05-14 | |
| SC TO-T/A | — | 2026-05-18 | — | |
| 10-Q | — | 2026-05-05 | 2026-03-31 | |
| 8-K | — | 2026-05-05 | — | |
| SC TO-T/A | — | 2026-04-29 | — | |
| SC TO-T/A | — | 2026-04-28 | — | |
| SC TO-T | — | 2026-04-20 | — | |
| DEFA14A | — | 2026-04-15 | — | |
| DEF 14A | — | 2026-04-15 | — | |
| ARS | — | 2026-04-15 | 2025-12-31 | |
| SC TO-C | — | 2026-04-07 | — | |
| SC TO-C | — | 2026-04-06 | — | |
| SC TO-C | — | 2026-04-06 | — | |
| 8-K | — | 2026-04-06 | 2026-04-05 | |
| 8-K | — | 2026-02-11 | — | |
| 10-K | — | 2026-02-11 | 2025-12-31 | |
| 8-K | — | 2025-11-24 | 2025-11-21 | |
| 10-Q | — | 2025-10-28 | 2025-09-30 | |
| 8-K | — | 2025-10-28 | — | |
| 8-K | — | 2025-07-30 | — | |
| 10-Q | — | 2025-07-30 | 2025-06-30 | |
| 8-K | — | 2025-05-30 | — | |
| 8-K | — | 2025-05-22 | 2025-05-21 | |
| 10-Q | — | 2025-05-05 | 2025-03-31 | |
| 8-K | — | 2025-05-05 | — | |
| ARS | — | 2025-04-09 | 2024-12-31 | |
| DEF 14A | — | 2025-04-09 | — | |
| DEFA14A | — | 2025-04-09 | — | |
| 8-K | — | 2025-04-04 | 2025-04-02 | |
| 10-K | — | 2025-02-10 | 2024-12-31 | |
| 8-K | — | 2025-02-06 | — | |
| 8-K | — | 2025-01-27 | 2025-01-24 | |
| 8-K | — | 2024-12-20 | — | |
| 8-K | — | 2024-11-01 | 2024-10-31 | |
| 10-Q | — | 2024-10-30 | 2024-09-30 | |
| 8-K | — | 2024-10-30 | — | |
| 8-K | — | 2024-10-11 | — | |
| 8-K | — | 2024-08-28 | — | |
| 10-Q | — | 2024-08-01 | 2024-06-30 | |
| 8-K | — | 2024-08-01 | — | |
| 8-K | — | 2024-05-28 | 2024-05-24 |
Showing 1–50 of 134 filings
Key facts
CIK
914475
CUSIP
64125C109
13F (30d)
195 filings
184 filers
Visit website
Investor relations